Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kiniksa Pharmaceuticals International, plc KNSA

Healthcare  —  Drug Manufacturers Specialty & Generic
75.08 (0.26) (0.35%) as of 25 Sep
Market cap
$5.9B
P/E
70.2×
Cash Flow Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Revenue

+8 more TTM periods

 597.97 677.56 754.05 840.85
Cost of Revenue 74.62 77.67 80.60 85.57
Gross Profit 523.35 599.89 673.44 755.28
R&D Expenses 97.46 96.85 105.00 127.15
SG&A Expenses 180.03 196.27 213.89 230.90
Operating Income 38.15 77.22 93.22 100.25
Non-operating Income/Expense 10.47 11.65 12.77 14.00
EBT 48.62 88.87 105.98 114.25
Income Tax Provision 12.70 29.86 32.93 33.59
Income after Tax 35.92 59.01 73.06 80.66
Net Income Common 35.92 59.01 73.06 80.66
EPS (Basic) 0.49 0.80 0.98 1.07
Gross Margin 87.52% 88.54% 89.31% 89.82%
EBIT Margin 6.38% 11.40% 12.36% 11.92%
EBT margin 8.13% 13.12% 14.06% 13.59%
Net Profit Margin 6.01% 8.71% 9.69% 9.59%
Free Cash Flow Margin 17.01% 20.13% 21.78% 21.74%
EBITDA 39.64 78.78 94.89 102.04
EBIT 38.15 77.22 93.22 100.25
EPS (Diluted, from Cont. Ops) 0.45 0.75 0.91 0.99
EPS (Basic, Consolidated) 0.48 0.80 0.97 1.06
EPS (Basic, from Continuous Ops) 0.48 0.80 0.97 1.06
Income from Continuous Operations 35.92 59.01 73.06 80.66
Consolidated Net Income/Loss 35.92 59.01 73.06 80.66
EBITDA Margin 6.63% 11.63% 12.58% 12.14%
Operating Cash Flow Margin 17.20% 20.36% 22.00% 22.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates